Poniard Pharmaceuticals Inc. Stock Analysis PARD
Poniard Pharmaceuticals, Inc. is a bio-pharmaceutical company, which focuses on the development and commercialization of oncology products. The company is headquartered in Seattle, Washington and currently employs 7 full-time employees. The company went IPO on 2011-12-30. The firm focuses on the development and commercialization of oncology products to impact the lives of people with cancer. The company develops picoplatin, a platinum-based chemotherapeutic agent that is in clinical development for multiple cancer indications, treatment combinations and by two routes of administration. The firm has offices in San Francisco, California; and Seattle, Washington in United States.
Read More Poniard Pharmaceuticals Inc (PARD) Chart
Key Statistics of Poniard Pharmaceuticals Inc (PARD)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.00Volume
100.00P/E Ratio (TTM)
-52 Week Range
Market Cap
15.00Avg. Volume
100.00Dividend Yield
-Financial Metrics & Statements of Poniard Pharmaceuticals Inc (PARD)
FAQ's for Poniard Pharmaceuticals Inc (PARD)
- According to Musaffa’s Shariah screening methodology, Poniard Pharmaceuticals Inc (PARD) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.